GTBIF - Pennsylvania Pulls Flavored Vapes From Market
It seems Pennsylvania’s medical marijuana program has pulled flavored vapes. Last week, On February 2, 2022, the Pennsylvania Department of Health (DOH) posted a list of known additives that it says were not approved by the FDA (Food & Drug Administration) for inhalation. Then on Friday February 4, 2022, the Pennsylvania DOH issued a withdrawal of these products by many of the leading cannabis companies in the state. The products mostly seem to include flavors like citrus, candies and cookies.
The DOH sent a letter to patients and caregivers on February 4th saying that some of the additives were approved by the FDA in non-inhalable products, but were not approved for inhalable products. They issued a mandatory recall for all the products.
The companies included on the list were:
- AES Compassionate Care
- Agri-Kind
- CannTech PA
- Cresco Labs
- Curaleaf (OTC: CURLF)
- FarmaceuticalRX
- Franklin Labs
- Greenleaf Medical
- Goodblend Pennsylvania
- GTI Pennsylvania (OTC: GTBIF)
- Holistic Farms
- Ilera Healthcare
- Insa
- MLH Explorations
- Pennsylvania Medical Solutions
- PennAlt Organics
- PurePenn
One company not on the list was Tilt Holdings (OTC: TLLTF), which wasted no time in letting the market know it wasn’t included.
“We have always been intently focused on manufacturing products that are safe, consistent, and effective for our patients,” said CEO Gary Santo. “While we do not have enough information available to comment on the DOH’s stance with respect to the use of certain additives, we want to make it clear to our patients, investors and other stakeholders that none of our products were named in the recall. TILT will continue to support our brand partners and other cannabis operators as the regulated industry seeks a resolution that prioritizes product conformance to the new additive restrictions released by the Pennsylvania DOH on Friday.”
Pittsburgh Business Times reported that since 2018, “There have been $2.8 billion in total sales, including $1.1 billion from growers and producers to dispensaries and $1.7 billion from the dispensaries to more than 582,000 registered patients and caregivers.”